Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 24, Issue 6, 2014, Pages 670-676

  Calanna, S ^a   Scicali, R ^a   Di Pino, A ^a   Knop, F K ^b,c   Piro, S ^a   Rabuazzo, A M ^a   Purrello, F ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Apolipoprotein; Cardiovascular risk; Liver steatosis; Prediabetes; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; APOA1 PROTEIN, HUMAN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BODY FAT; CONTROLLED STUDY; DISORDERS OF LIPID METABOLISM; ECHOGRAPHY; FATTY LIVER; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BODY COMPOSITION; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; EPIDEMIOLOGY; FEMALE; HYPERTENSION; INSULIN RESISTANCE; ITALY; LIVER; MALE; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PREDIABETIC STATE; PREVALENCE; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADULT; APOLIPOPROTEIN A-I; BODY COMPOSITION; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; INSULIN RESISTANCE; ITALY; LIPIDS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDIABETIC STATE; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84901501650     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.01.013     Document Type: Article

References (36)

1. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013, 36(Suppl. 1):S67-S74.
2. Edelman D., Olsen M.K., Dudley T.K., Harris A.C., Oddone E.Z. Utility of hemoglobin A1c in predicting diabetes risk. J Gen Intern Med 2004, 19:1175-1180.
3. Lorenzo C., Hartnett S., Hanley A.J., Rewers M.J., Wagenknecht L.E., Karter A.J., et al. Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study. J Clin Endocrinol Metab 2013, 98:1622-1630.
4. Garg A., Grundy S.M. Management of dyslipidemia in NIDDM. Diabetes Care 1990, 13:153-169.
5. Carnevale Schianca G.P., Pedrazzoli R., Onolfo S., Colli E., Cornetti E., Bergamasco L., et al. ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutr Metab Cardiovasc Dis 2011, 21:406-411.
6. Angulo P., Keach J.C., Batts K.P., Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-1362.
7. Li X., Xia M., Ma H., Hu Y., Yan H., He W., et al. Liver fat content, evaluated through semi-quantitative ultrasound measurement, is associated with impaired glucose profiles: a community-based study in Chinese. PloS One 2013, 8:e65210.
8. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc Mayo Clin 1980, 55:434-438.
9. Ismail M.H. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic. Am J Med Sci 2011, 341:485-492.
10. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
11. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
12. Gaede P., Vedel P., Larsen N., Jensen G.V.H., Parving H.-H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
13. Abraham T.M., Fox C.S. Implications of rising prediabetes prevalence. Diabetes Care 2013, 36:2139-2141.
14. Royal College of Physicians Report: The Medical Consequences of Alcohol Abuse, a Great and Growing Evil 1987.
15. Mosca A., Goodall I., Hoshino T., Jeppsson J.O., John W.G., Little R.R., et al. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med CCLM FESCC 2007, 45:1077-1080.
16. Calanna S., Piro S., Di Pino A., Maria Zagami R., Urbano F., Purrello F., et al. Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis. Obesity 2013, 21:320-325.
17. Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006, 6:33.
18. Spadaro L., Alagona C., Palermo F., Piro S., Calanna S., Parrinello G., et al. Early phase insulin secretion is increased in subjects with normal fasting glucose and metabolic syndrome: a premature feature of beta-cell dysfunction. Nutr Metab Cardiovasc Dis 2011, 21:206-212.
19. Shah A.G., Lydecker A., Murray K., Tetri B.N., Contos M.J., Sanyal A.J., et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2009, 7:1104-1112.
20. Wang W., Khan S., Blackett P., Alaupovic P., Lee E. Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes. J Clin Lipidol 2013, 7:38-42.
21. Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States 2011, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
22. Lazo M., Selvin E., Clark J.M. Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med 2008, 148:348-352.
23. Dasarathy S., Dasarathy J., Khiyami A., Joseph R., Lopez R., McCullough A.J. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009, 51:1061-1067.
24. Sung K.-C., Rhee E.-J., Kim H., Park J.-B., Kim Y.-K., Woo S., et al. An elevated apolipoprotein B/AI ratio is independently associated with microalbuminuria in male subjects with impaired fasting glucose. Nutr Metab Cardiovasc Dis 2011, 21:610-616.
25. Wägner A.M., Pérez A., Calvo F., Bonet R., Castellví A., Ordóñez J. Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. Diabetes Care 1999, 22:812-817.
26. Ford E.S., Li C., Sniderman A. Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008. Cardiovasc Diabetol 2013, 12:26.
27. Siegel R.D., Cupples A., Schaefer E.J., Wilson P.W. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 1996, 45:1267-1272.
28. Janssen I., Heymsfield S.B., Wang Z.M., Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol 1985, 2000(89):81-88.
29. Christman A.L., Lazo M., Clark J.M., Selvin E. Low glycated hemoglobin and liver disease in the U.S. population. Diabetes Care 2011, 34:2548-2550.
30. Calori G., Lattuada G., Ragogna F., Garancini M.P., Crosignani P., Villa M., et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011, 54:145-152.
31. Lerchbaum E., Pilz S., Grammer T.B., Boehm B.O., Stojakovic T., Obermayer-Pietsch B., et al. The fatty liver index is associated with increased mortality in subjects referred to coronary angiography. Nutr Metab Cardiovasc Dis 2013, 23:1231-1238.
32. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
33. Chen Y.D., Golay A., Swislocki A.L., Reaven G.M. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987, 64:17-21.
34. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453-458.
35. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008, 51:1947-1953.
36. Sung K.-C., Wild S.H., Byrne C.D. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013.